Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q3 EPS of ($0.33), $0.09 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $44.75 million versus the consensus estimate of $37.62 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.